News

The US growth rate for spending on medicines is expected to fall in 2016 and beyond, according to new research.

As more biosimilars are approved, plans and PBMs will continue to evolve their strategies regarding coverage and formulary management of these new medications.

President-elect Trump named Tom Price and Seema Verma to lead HHS and CMS, respectively. Here’s what you should know about them.

Inherited susceptibilities to leukemias are becoming better understood and have important implications for screening, prevention, genetic counseling, and treatment.

Investigational gene therapies might reduce the suffering and death caused by this genetic disease.

As development of molecular biomarkers hastens, administrators, clinicians and regulators are working to organize and define biomarkers’ appropriate roles in clinical care-and discussing how to efficiently share the massive amounts of genomic data that will result.

CMS is adding, dropping, and expanding payment rules

Hospitals and health systems that treat some of the country’s most vulnerable populations face complex challenges when working to improve population health.

None of Trump’s plans, such as repealing parts of Obamacare or expanding HSAs, will rein in the rising cost of healthcare.

FDA’s approval of a new indication for empagliflozin (Jardiance, Eli Lilly and Boehringer Ingelheim) could net the pharmaceutical manufacturers more than $1 billion.

Plans and PBMs are finding new ways to rein in pharmacy costs.

Telephonic and personalized diabetes self-education programs which fit into patient’s busy lives will make a greater impact than in-person classes only.

In this Q&A, a physician and lymphoma expert discusses treatment advances and promising signs for the future.

Will President-elect Donald Trump affect the outcome of the Anthem-Cigna and Aetna-Humana mergers?

An ASH presenter describes how better health IT and better institutional practices are necessary to leverage EHRs for quality of care.

Novel immunotherapy treatments are showing promise for patients with acute lymphoblastic leukemia (ALL), but they can trigger cytokine release syndrome.

Immune checkpoint inhibitors are taking the stage in treating relapsed and refractory Hodgkin lymphoma. Read more.

Joint ventures are gaining steam as health plans and providers look for new ways to work together.

Two new major studies on a biosimilar to trastuzumab (Herceptin, Genentech) to treat HER2-positive metastatic breast cancer and HER2-positive gastric cancer demonstrated equivalency.

Two experts discuss top-of-mind women’s healthcare issues in managed care.

Does your analytics team have what it takes? Experts share their top recommendations.

From “all-in-one” healthcare appointments to coordinating women’s care for convenience, here’s how providers and researchers say plans and providers can prioritize

The AMA and medical schools across the country are placing new emphasis on population health management and value-based care.

Experts share how Trump could change Obamacare coverage, accessibility, affordability, Medicare/Medicaid, price transparency, and more.

Here’s how one non-profit health plan harnessed the power of medical and pharmacy data to rein in drug costs.

Two new diabetes drugs, both long-acting injectable insulin products, were simultaneously approved by FDA.

Leader of the YMCA’s Diabetes Prevention Program explains how it is improving diabetes care.

The Independence Blue Cross Foundation Healthy Hearts Initiative aims to improve survival rates for sudden cardiac arrest, increase CPR preparedness.